Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45

Cancer

Volumn 117, Issue 14, 2011, Pages 3135-3147

  Li, Hua ^a   Adachi, Yasushi ^a   Yamamoto, Hiroyuki ^a   Min, Yongfen ^a,b   Ohashi, Hirokazu ^a   Ii, Masanori ^a   Arimura, Yoshiaki ^a   Endo, Takao ^a   Lee, Choon Taek ^c   Carbone, David P ^b   Imai, Kohzoh ^a   Shinomura, Yasuhisa ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

angiogenesis; gastric cancer; insulin like growth factor I receptor; lymphangiogenesis; vascular endothelial growth factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOVIRUS VECTOR; BEVACIZUMAB; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN C; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CELL STRAIN MKN45; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHANGIOGENESIS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959990517     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25893     Document Type: Article

References (47)

1. Baserga R., Oncogenes and the strategy of growth factors. Cell. 1994; 79: 927-930.
2. Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986; 5: 2503-2512.
3. Yu H, Rohan T., Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92: 1472-1489.
4. Remacle-Bonnet M, Garrouste F, el Atiq F, Roccabianca M, Marvaldi J, Pommier G., Des-(1-3)-IGF-I, an insulin-like growth factor analog used to mimic a potential IGF-II autocrine loop, promotes the differentiation of human colon-carcinoma cells. Int J Cancer. 1992; 52: 910-917. (Pubitemid 23009508)
5. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999; 91: 620-625. (Pubitemid 29194048)
6. Harper J, Burns JL, Foulstone EJ, Pignatelli M, Zaina S, Hassan AB., Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res. 2006; 66: 1940-1948.
7. Foulstone E, Prince S, Zaccheo O, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol. 2005; 205: 145-153. (Pubitemid 40227987)
8. Adachi Y, Yamamoto H, Imsumran A, et al. Insulin-like growth factor-I receptor as a candidate for a novel molecular target in the gastrointestinal cancers. Dig Endosc. 2006; 18: 245-251. (Pubitemid 44341870)
9. Baserga R., The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 1995; 55: 249-252.
10. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R., Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A. 1993; 90: 11217-11221. (Pubitemid 23354400)
11. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A., Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993; 75: 59-72. (Pubitemid 23306021)
12. Thompson MA, Cox AJ, Whitehead RH, Jonas HA., Autocrine regulation of human tumor cell proliferation by insulin-like growth factor II: an in-vitro model. Endocrinology. 1990; 126: 3033-3042. (Pubitemid 20216558)
13. Shiraishi T, Mori M, Yamagata M, Haraguchi M, Ueo H, Sugimachi K., Expression of insulin-like growth factor 2 mRNA in human gastric cancer. Int J Oncol. 1998; 13: 519-523. (Pubitemid 28372675)
14. Pavelic K, Kolak T, Kapitanovic S, et al. Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol. 2003; 201: 430-438. (Pubitemid 37408264)
15. Wang Y, Adachi Y, Imsumran A, et al. Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human digestive/gastrointestinal cancers. J Gastroenterol. 2010; 45: 159-170.
16. Simmons JG, Pucilowska JB, Lund PK., Autocrine and paracrine actions of intestinal fibroblast-derived insulin-like growth factors. Am J Physiol. 1999; 276: G817-827. (Pubitemid 29214093)
17. Adachi Y, Li R, Yamamoto H, et al. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin. Carcinogenesis. 2009; 30: 1305-1313.
18. Shibuya M, Claesson-Welsh L., Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006; 312: 549-560. (Pubitemid 43290332)
19. Ellis LM, Hicklin DJ., VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8: 579-591.
20. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T., Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol. 1997; 15: 826-832. (Pubitemid 27074254)
21. Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res. 1999; 5: 1823-1829. (Pubitemid 29334464)
22. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996; 77: 858-863. (Pubitemid 26061277)
23. Juttner S, Wissmann C, Jons T, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: 2 novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006; 24: 228-240. (Pubitemid 46622052)
24. Yonemura Y, Endo Y, Tabata K, et al. Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. Int J Clin Oncol. 2005; 10: 318-327. (Pubitemid 41507205)
25. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D., Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002; 62: 1030-1035. (Pubitemid 34160283)
26. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB., Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. 1996; 271: 29483-29488. (Pubitemid 26382669)
27. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM., Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res. 1998; 58: 4008-4014. (Pubitemid 28405661)
28. Stoeltzing O, Liu W, Reinmuth N, et al. Regulation of hypoxia-inducible factor-1 alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol. 2003; 163: 1001-1011. (Pubitemid 37040136)
29. Neid M, Datta K, Stephan S, et al. Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J Biol Chem. 2004; 279: 3941-3948. (Pubitemid 38198977)
30. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM., The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008; 14: 6364-6370.
31. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342. (Pubitemid 38702844)
32. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 2003; 63: 8912-8921. (Pubitemid 38064071)
33. Piao W, Wang Y, Adachi Y, et al. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther. 2008; 7: 1483-1493.
34. Adachi Y, Lee CT, Coffee K, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology. 2002; 123: 1191-1204.
35. Min Y, Adachi Y, Yamamoto H, et al. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res. 2003; 63: 6432-6441. (Pubitemid 37255193)
36. Min Y, Adachi Y, Yamamoto H, et al. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut. 2005; 54: 591-600. (Pubitemid 40559239)
37. Imsumran A, Adachi Y, Yamamoto H, et al. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis. 2007; 28: 947-956. (Pubitemid 47072177)
38. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M., Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008; 14: 5459-5465.
39. Reinmuth N, Liu W, Fan F, et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res. 2002; 8: 3259-3269. (Pubitemid 35155039)
40. Reinmuth N, Fan F, Liu W, et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest. 2002; 82: 1377-1389. (Pubitemid 35191541)
41. Bauer TW, Fan F, Liu W, et al. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice. Ann Surg Oncol. 2007; 14: 2838-2846. (Pubitemid 47460648)
42. Moser C, Schachtschneider P, Lang SA, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer. 2008; 44: 1577-1586.
43. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL., Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002; 277: 38205-38211. (Pubitemid 35154674)
44. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ,. The insulin-like growth factor-1 receptor-targeting antibody, CP-751871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 2009; 69: 7662-7671.
45. Tang Y, Zhang D, Fallavollita L, Brodt P., Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res. 2003; 63: 1166-1171. (Pubitemid 36348689)
46. Bjorndahl M, Cao R, Nissen LJ, et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci U S A. 2005; 102: 15593-15598. (Pubitemid 41528101)
47. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008; 49: 522-527.